New drug combo shows promise for Hard-to-Treat ovarian cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have biopsy-confirmed high grade serous epithelial ovarian cancer. * Patients must present with stage III or IV disease and be appropriate to receive neoadjuvant chemotherapy * Patients must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low-risk, medically routine procedure for immunohistochemistry (IHC) confirmation of FRα positivity * Patients must have a performance status of 0 or 1. * Patient's tumor must be positive for FRα expression as defined by a score of PS2+ intensity in \>75% of cells * Patients must have adequate hematologic, liver and kidney functions defined as: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL) * Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the prior 10 days * Hemoglobin ≥ 9.0 g/dL * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN * Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN) * Serum albumin ≥ 2 g/dL * Patients must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirements * Women of childbearing potential (WCBP) must agree to use highly effective contraceptive method(s) (as defined in Section 5.8.6 while on MIRV and for at least 4 months after the last dose * WCBP must have a negative pregnancy test within the 4 days prior to the first dose of MIRV Exclusion Criteria: * Patients who have previously been treated with a systemic anti-cancer therapy * Patients with low-grade serous, endometrioid, clear cell, or mucinous histology * Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision * Patients with serious concurrent illness or clinically relevant active infection, including, but not limited to the following: * History of hepatitis B or C infection (whether or not on active antiviral therapy) * History of human immunodeficiency virus (HIV) infection * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV * Patients with a history of multiple sclerosis (MS) or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome) * Patients with clinically significant cardiac disease including, but not limited to, any of the following: * Myocardial infarction ≤ 6 months prior to first dose * Unstable angina pectoris * Uncontrolled congestive heart failure (New York Heart Association \> class II) * Uncontrolled ≥ Grade 3 hypertension (per CTCAE) * Uncontrolled cardiac arrhythmias * Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment * Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C) * Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD), including noninfectious pneumonitis * Patients requiring use of folate-containing supplements (eg, folate deficiency) * Patients with prior hypersensitivity to monoclonal antibodies (mAb) * Women who are pregnant or breastfeeding * Patients who received prior treatment with MIRV or other FRα-targeting agents * Patients with untreated or symptomatic central nervous system (CNS) metastases * Patients with a history of other malignancy within 3 years prior to enrollment Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible